ethchlorvynol (placidyl) Report issue

Small molecule Approved FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Ethchlorvynol is used to treat insomnia (trouble in sleeping). It developed by Pfizer in the 1950s. In the United States it was sold by Abbott Laboratories under the tradename Placidyl. Although the exact mechanism of action is unknown, ethchlorvynol appears to depress the central nervous system in a manner similar to that of barbiturates – by means of GABA-A receptors modulation. Moderate side effects are: Skin rash or hives; dizziness or faintness; unusual excitement, nervousness, or restlessness. It is addictive and after prolonged use can cause withdrawal symptoms including convulsions, hallucinations, and memory loss.   NCATS

Chemistry

  • SMILES: CCC(O)(\C=C\Cl)C#C
  • InChIKey: ZEHYJZXQEQOSON-AATRIKPKSA-N
  • Mol. Mass: 144.599
  • ALogP: 1.51
  • ChEMBL Molecule:
    ethchlorvynol  
More Chemistry

Pharmacology

Alternative names

1-chloro-3-ethyl-1-penten-4-yn-3-ol | 1-chloro-3-ethyl-pent-1-en-4-yn-3-ol | 3-(beta-chlorovinyl)-1-pentyn-3-ol | 3-(β-chlorovinyl)-1-pentyn-3-ol | alvinol | arvynol | ethchlorvynol | ethychlorvynol | ethyl β-chlorovinyl ethynyl carbinol | placidyl | β-chlorovinyl ethyl ethynyl carbinol

Organizations (2)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Sleep Initiation and Maintenance Disorders (approved 1961)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue